Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T90035
|
|||||
| Target Name |
MERS-CoV spike glycoprotein S2 subunit (S S2)
|
|||||
| Synonyms |
MERS-CoV S glycoprotein S2 subunit; MERS-CoV E2 S2 subunit; MERS-CoV Peplomer protein S2 subunit
Click to Show/Hide
|
|||||
| Gene Name |
MERS-CoV S
|
|||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Middle East Respiratory Syndrome [ICD-11: 1D64] | |||||
| Function |
Mediates fusion of the virion and cellular membranes by acting as a class I viral fusion protein. Under the current model, the protein has at least three conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During viral and target cell membrane fusion, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes.
Click to Show/Hide
|
|||||
| BioChemical Class |
Betacoronaviruses spike protein family
|
|||||
| UniProt ID | ||||||
| Sequence |
TPSTLTPRSVRSVPGEMRLASIAFNHPIQVDQLNSSYFKLSIPTNFSFGVTQEYIQTTIQ
KVTVDCKQYVCNGFQKCEQLLREYGQFCSKINQALHGANLRQDDSVRNLFASVKSSQSSP IIPGFGGDFNLTLLEPVSISTGSRSARSAIEDLLFDKVTIADPGYMQGYDDCMQQGPASA RDLICAQYVAGYKVLPPLMDVNMEAAYTSSLLGSIAGVGWTAGLSSFAAIPFAQSIFYRL NGVGITQQVLSENQKLIANKFNQALGAMQTGFTTTNEAFRKVQDAVNNNAQALSKLASEL SNTFGAISASIGDIIQRLDVLEQDAQIDRLINGRLTTLNAFVAQQLVRSESAALSAQLAK DKVNECVKAQSKRSGFCGQGTHIVSFVVNAPNGLYFMHVGYYPSNHIEVVSAYGLCDAAN PTNCIAPVNGYFIKTNNTRIVDEWSYTGSSFYAPEPITSLNTKYVAPQVTYQNISTNLPP PLLGNSTGIDFQDELDEFFKNVSTSIPNFGSLTQINTTLLDLTYEMLSLQQVVKALNESY IDLKELGNYTYYNKWPWYIWLGFIAGLVALALCVFFILCCTGCGTNCMGKLKCNRCCDRY EEYDLEPHKVHVH Click to Show/Hide
|
|||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Preclinical Drugs | [+] 4 | + | ||||
| 1 | HR1P peptide | Drug Info | Preclinical | Middle East Respiratory Syndrome (MERS) | [1] | |
| 2 | HR2P peptide | Drug Info | Preclinical | Middle East Respiratory Syndrome (MERS) | [1] | |
| 3 | HR2P-M1 peptide | Drug Info | Preclinical | Middle East Respiratory Syndrome (MERS) | [1] | |
| 4 | HR2P-M2 peptide | Drug Info | Preclinical | Middle East Respiratory Syndrome (MERS) | [1] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Inhibitor | [+] 4 Inhibitor drugs | + | ||||
| 1 | HR1P peptide | Drug Info | [1] | |||
| 2 | HR2P peptide | Drug Info | [1] | |||
| 3 | HR2P-M1 peptide | Drug Info | [1] | |||
| 4 | HR2P-M2 peptide | Drug Info | [1] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun. 2014;5:3067. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.